Veterinary Arthroscopy Devices Market By Product Type (Arthroscopes, Visualization Systems, Fluid Management Systems, Powered Resection Systems, Arthroscopic Hand Instruments, Accessories and Consumables), By Application (Diagnostic Arthroscopy, Surgical/Therapeutic Arthroscopy), By Animal Type (Companion Animals [Dogs, Cats], Large Animals [Horses, Other Large Animals]), By End User (Veterinary Hospitals, Veterinary Clinics, Veterinary Specialty and Referral Centers, Academic and Research Institutes), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Veterinary Arthroscopy Devices Market: Expanding Role of Minimally Invasive Joint Surgery, Advanced Imaging Technologies, and Growing Clinical Adoption in Companion and Equine Orthopedics

The Global Veterinary Arthroscopy Devices Market was valued at USD 0.46 billion in 2025 and is projected to reach USD 0.70 billion by 2032, expanding at a CAGR of 6.2% during 2026–2032.

 

Veterinary arthroscopy devices are specialized minimally invasive instruments used to look inside animal joints and help diagnose or treat joint problems, especially in dogs and horses. A full system typically includes small cameras (arthroscopes), imaging and video systems, light sources, fluid irrigation equipment, and surgical tools for cutting, cleaning, or removing damaged tissue. Demand for these devices increases when veterinarians need to move beyond X-rays or scans and directly examine the inside of a joint to remove fragments, assess cartilage, treat meniscal injuries, or perform biopsies. These systems are mainly used in specialist animal hospitals and equine surgery centers, although newer, smaller visualization technologies are making arthroscopy more accessible and easier to use in a wider range of veterinary settings.

 

FDA-approved NSAIDs such as carprofen (RIMADYL), deracoxib, firocoxib, meloxicam, grapiprant, and robenacoxib are commonly used for perioperative pain and inflammation management in dogs undergoing orthopedic arthroscopy, but they do not replace or influence the need for arthroscopic procedures, and veterinary arthroscopy devices themselves are regulated under FDA animal-device rules but, unlike human medical devices, do not require premarket approval (510(k) or PMA), meaning market success depends primarily on clinical performance, surgeon adoption, training, and service support rather than regulatory clearance.

 

Why Are Canine Orthopedic Cases Creating Recurring Arthroscopy Demand?

Canine orthopedic disease—particularly elbow, shoulder, and stifle disorders—represents a key and recurring driver of veterinary arthroscopy demand. A VetCompass epidemiological study of 455,069 dogs under primary veterinary care reported a one-year elbow-joint disease prevalence of approximately 0.56%, with osteoarthritis frequently recorded among affected cases. Breeds such as Rottweilers, Labrador Retrievers, German Shepherd Dogs, and Golden Retrievers showed higher odds of disease. While not all cases require surgery, persistent lameness, suspected fragmented medial coronoid process, elbow dysplasia, and cases requiring direct joint evaluation often progress to specialist referral, where arthroscopy becomes a preferred diagnostic and therapeutic tool.

Clinical utilization data further reinforce the repeat-use nature of arthroscopy. In a study of 750 elective canine elbow arthroscopies over ten years, Perry and Li reported a 4.8% rate of major complications requiring repeat surgery. Beyond clinical outcomes, high procedural volumes in referral hospitals drive continuous consumption of arthroscopy blades, burs, irrigation systems, and other consumables, while also supporting recurring demand for scope servicing and equipment upgrades.

Shoulder osteochondrosis, particularly osteochondritis dissecans (OCD), adds another consistent demand stream. OCD involves abnormal cartilage formation that can detach and cause pain and joint dysfunction, often requiring arthroscopic removal and joint surface evaluation. This reinforces the need for small-diameter scopes and specialized grasping and resection instruments.

Stifle procedures, especially those related to cranial cruciate ligament (CCL) disease, represent a larger adjacent opportunity. While not all CCL surgeries use arthroscopy, it is increasingly used for intra-articular assessment and meniscal evaluation in conjunction with reconstructive procedures. Adoption of arthroscopy in these cases directly increases device utilization in referral-based orthopedic workflows.

 

Why Does Equine Arthroscopy Remain a High-Value Procedure Segment?

Equine arthroscopy represents a mature and high-value segment within veterinary minimally invasive surgery. ACVS identifies arthroscopy as a key approach for managing osteochondritis dissecans, intra-articular fragments, cartilage lesions, and other joint pathologies. OCD is particularly relevant in young performance horses, where joint abnormalities can significantly impact athletic function and are often identified during pre-purchase or performance evaluations. Clinical signs are reported in approximately 5%–25% of equine OCD cases, depending on lesion severity and location.

Procedure volume data further support the segment’s stability. In a study of 357 horses undergoing 366 elective arthroscopic procedures, Secor and colleagues found that 168 procedures were performed on an outpatient basis and 198 required hospitalization, with no increased complication risk associated with outpatient management in appropriately selected cases. This supports efficient case throughput and sustained utilization of arthroscopy towers, pumps, and powered instrumentation.

Equine arthroscopy also requires specialized equipment configurations, including longer instruments and systems adapted to larger joints and different surgical positioning. This creates a distinct purchasing cycle compared with small-animal applications and supports demand for both conventional systems and emerging minimally invasive approaches such as standing or needle arthroscopy.

 

How Are Nano-Arthroscopy and Micro-Visualization Changing Device Demand?

A major shift in the market is the transition toward smaller and more flexible visualization systems. Traditional small-animal arthroscopy typically uses scopes in the 1.9-mm to 2.7-mm range, with companies such as KARL STORZ and Arthrex Vet Systems offering established platforms in this category.

Arthrex has advanced this trend through its NanoScope platform, which integrates a 1-mm imaging sensor, LED illumination, image management, and touchscreen control, along with approximately 2-mm instruments for diagnostic and operative use. Its single-use camera design shifts part of the revenue model from capital equipment toward procedure-linked consumables, increasing recurring revenue potential.

Clinical applications are also expanding beyond traditional joints. In 2026, UC Davis reported early clinical use of 1.9-mm nano-arthroscopy for canine temporomandibular joint (TMJ) disorders, including four initial cases and multi-institutional training workshops. The technique enables direct visualization and biopsy of joint structures that are not accessible through CT imaging alone. While still in early adoption, it demonstrates how smaller systems can enable entirely new arthroscopic indications.

Biovision’s 1.2-mm NeedleView system represents another approach to miniaturization, offering ultra-compact visualization with associated cannulas and instruments for both small-animal and equine use. Movora, through VetClarity’s VetFocus Micro platform, complements this with structured training programs focused on scope handling, triangulation, and procedural confidence. These initiatives highlight that adoption depends not only on device availability but also on surgeon training and familiarity.

 

How Are Pet Insurance and Veterinary Price Sensitivity Affecting Procedure Conversion?

Pet insurance is an important enabler of advanced veterinary procedures, including arthroscopy. NAPHIA reported 7.6 million insured pets in North America in 2025, with premiums reaching approximately USD 6.2 billion, reflecting steady market growth.

Dogs account for most insured pets in the U.S., where penetration is about 5.46%. Insurance increases the likelihood that owners proceed from diagnosis to advanced surgical treatment, especially in specialist-referred orthopedic cases requiring imaging, anesthesia, and arthroscopy.

However, most pets remain uninsured, and cost sensitivity among owners is rising. AVMA reports highlight concerns over veterinary expenses and declining visit volumes. As a result, arthroscopy adoption is split: insured or higher-income clients are more likely to proceed, while self-pay cases may delay or avoid surgery.

 

Why Does Specialist Availability Limit the Speed of Market Expansion?

Adoption of arthroscopy is closely tied to the availability of trained veterinary surgeons. ACVS reports approximately 2,686 board-certified veterinary surgeons, with a significant proportion specializing in small-animal orthopedics or equine surgery. These specialists are concentrated in private referral hospitals and specialty centers, which serve as the primary sites for arthroscopy procedures.

In Europe, ECVS reports 1,118 Diplomates across 39 countries, reflecting a similarly concentrated specialist base. While general practitioners may assist in diagnosis and referral, arthroscopy remains largely dependent on specialist execution, limiting widespread decentralized adoption.

Training and education therefore play a critical role in market expansion. Vendors and professional organizations increasingly invest in wet labs, simulation training, and hands-on workshops to improve surgeon confidence in portal placement, instrument handling, and intra-articular navigation. Without this capability development, even advanced equipment may remain underutilized.

 

How Veterinary Arthroscopy Is Evolving Beyond Traditional Device Categories?

Product Types Account for Veterinary Arthroscopy Device Revenue

Arthroscopes represented 22.0% of the market, equivalent to approximately USD 0.10 billion in 2025, and are projected to expand at a 6.0% CAGR. Demand remains anchored in replacement of reusable scopes, expansion of orthopedic procedure capacity, and adoption of smaller-diameter devices for canine and equine joints. High-volume referral centers also require multiple scope sizes and backup instruments to maintain operating-room availability when devices are being sterilized, serviced, or repaired.

Visualization Systems accounted for 19.0% of the market, or approximately USD 0.09 billion, and are expected to grow at a comparatively faster 6.8% CAGR. Purchases are increasing as specialty hospitals replace older camera towers with higher-resolution digital systems, integrate image capture and documentation into surgical workflows, and adopt compact visualization platforms capable of supporting multiple minimally invasive procedures. The shift toward chip-on-tip and micro-visualization technology further strengthens this upgrade cycle.

Fluid Management Systems held a 12.0% share, valued at approximately USD 0.06 billion in 2025, with a projected 5.9% CAGR. Their demand is tied directly to arthroscopic case volume because stable irrigation and joint distension are required to maintain visualization during procedures. Hospitals expanding surgical throughput need reliable pumps, tubing, inflow and outflow components, while recurring procedure volume creates replacement demand for associated disposable sets.

Powered Resection Systems represented 15.0% of the market, equivalent to around USD 0.07 billion, and are forecast to grow at a 6.5% CAGR. Increasing use of arthroscopy for therapeutic procedures rather than visualization alone supports demand for powered shavers and resection platforms used to remove abnormal cartilage, soft tissue and intra-articular debris. Suppliers that integrate resection consoles with visualization and irrigation systems can capture a larger portion of each surgical installation.

Arthroscopic Hand Instruments accounted for 18.0% of the market, or approximately USD 0.08 billion in 2025, and are expected to grow at a 5.7% CAGR. Graspers, probes, forceps, scissors, curettes and other slender instruments remain essential for fragment removal, tissue manipulation and joint assessment. Demand is driven by procedure volume, replacement of worn instruments, the need for joint-specific instrument dimensions, and expansion of arthroscopy into smaller anatomical spaces.

Accessories and Consumables represented 14.0% of the market, approximately USD 0.06 billion, while recording the fastest product-type CAGR at 7.0%. Unlike large capital systems, blades, burs, tubing, cannulas and other procedure-linked items generate repeat purchases as arthroscopic case volumes increase. Single-use and micro-arthroscopy components can further increase recurring revenue per procedure, making this segment strategically important for suppliers seeking revenue beyond initial system installation.

 

How Demand Is Divided Between Diagnostic and Surgical Arthroscopy?

Diagnostic Arthroscopy accounted for 26.0% of the market, valued at approximately USD 0.12 billion in 2025, and is projected to grow at a 5.5% CAGR. Its demand is concentrated in cases where radiography, CT or other imaging cannot provide sufficient direct assessment of cartilage, synovium, menisci or intra-articular lesions. Smaller scopes and needle-arthroscopy systems can broaden this use by reducing access size and making direct visualization practical in joints or clinical situations where conventional operative arthroscopy may be disproportionate.

Surgical/Therapeutic Arthroscopy dominated the application market with a 74.0% share, equivalent to approximately USD 0.34 billion, and is expected to expand at a 6.5% CAGR. The segment benefits from procedures involving fragment removal, cartilage debridement, meniscal assessment, biopsy and treatment of canine or equine joint pathology. Therapeutic cases also consume more components across the arthroscopy ecosystem, including powered resection systems, irrigation products, hand instruments, blades and burs, giving them greater revenue intensity than visualization-only procedures.

 

Which Animal Types Generate the Largest Arthroscopy Device Demand?

Companion Animals represented 68.0% of the market, or approximately USD 0.31 billion in 2025, and are projected to expand at a 6.7% CAGR. Growth is driven by increasing referral of canine orthopedic cases, wider access to specialty surgery, expanding pet-insurance coverage and owner willingness to pursue minimally invasive treatment for mobility-limiting joint disorders. Companion-animal hospitals also provide a larger recurring installed base for compact arthroscopy and visualization systems.

Within this group, Dogs accounted for 61.0% of the total market, approximately USD 0.28 billion, and are expected to record a 6.8% CAGR. Canine demand is supported by elbow dysplasia, shoulder OCD, stifle disease and other orthopedic conditions that frequently reach specialist referral centers. The availability of 1.9-mm, 2.4-mm and needle-sized arthroscopes further supports adoption across a wider range of canine joint procedures.

Cats represented a much smaller 7.0% share, equivalent to approximately USD 0.03 billion, and are projected to grow at a 5.9% CAGR. Arthroscopy remains less commonly performed in cats because of smaller joint dimensions and lower procedure volumes, but continued miniaturization of scopes and instruments can improve feasibility in selected orthopedic and diagnostic cases.

Large Animals accounted for 32.0% of the market, valued at approximately USD 0.15 billion, with a projected 5.2% CAGR. Demand is concentrated in equine hospitals, veterinary teaching institutions and surgical centers managing performance animals, where arthroscopy is established for joint fragments, OCD and other intra-articular pathology.

Horses alone represented 28.0% of the total market, approximately USD 0.13 billion in 2025, and are expected to grow at a 5.4% CAGR. Equine arthroscopy benefits from an established procedural role in sport, racing and performance horses, where preservation of joint function carries substantial clinical and economic importance. Requirements for dedicated large-joint instrumentation and continuing interest in standing arthroscopy also sustain equipment purchases.

Other Large Animals accounted for the remaining 4.0% share, or approximately USD 0.02 billion, and are projected to expand at a 4.3% CAGR. Adoption remains limited because arthroscopic intervention is concentrated in selected high-value breeding, production or research animals where the expected clinical or economic benefit can justify specialist surgery and equipment use.

 

Which End Users Generate the Most Veterinary Arthroscopy Device Purchases?

Veterinary Hospitals represented the largest end-user segment with a 34.0% market share, equivalent to approximately USD 0.16 billion in 2025, and are projected to grow at a 6.1% CAGR. Larger hospitals can justify complete arthroscopy installations because they combine higher orthopedic caseloads with operating-room infrastructure, anesthesia capability, sterilization services and access to multiple surgeons. Their purchasing requirements also extend beyond scopes into camera systems, pumps, powered resection equipment and recurring consumables.

Veterinary Clinics accounted for 26.0% of the market, approximately USD 0.12 billion, and are expected to expand at a 5.5% CAGR. Adoption is more selective because lower orthopedic case volumes can make full arthroscopy towers difficult to justify. Compact visualization systems, shared minimally invasive platforms and lower-cost modular equipment can improve the economics for clinics that are building surgical capability without operating as large referral hospitals.

Veterinary Specialty and Referral Centers represented 30.0% of the market, valued at approximately USD 0.14 billion in 2025, and are projected to record the fastest end-user CAGR at 7.1%. These centers concentrate board-certified surgeons, complex orthopedic referrals and higher procedure volumes, creating strong demand for premium visualization, multiple scope sizes, powered resection systems and procedure-linked consumables. Their higher utilization rates also support more frequent upgrades and replacement purchases.

Academic and Research Institutes accounted for 10.0% of the market, equivalent to approximately USD 0.05 billion, and are expected to grow at a 5.4% CAGR. Universities purchase arthroscopy systems for clinical referral services, resident and specialist training, minimally invasive surgery research and hands-on education. Public tenders such as GADVASU's procurement of 2.0-mm and 2.7-mm arthroscopes illustrate how academic investment can create equipment demand even in markets where private specialty infrastructure remains at an earlier stage.

 

Why North America Leads the Veterinary Arthroscopy Devices Market?

North America leads the veterinary arthroscopy market due to a combination of high pet ownership, strong specialist infrastructure, and relatively higher insurance penetration, accounting for a 40.0% market share valued at approximately USD 0.18 billion in 2025, and is projected to grow at a CAGR of 5.8%. The U.S. alone has approximately 87.3 million pet dogs, supported by a large network of referral hospitals and ACVS-certified surgeons capable of performing advanced orthopedic procedures.

Insurance coverage further strengthens market maturity, with the majority of insured pets in North America located in the U.S. This financial support increases the likelihood of elective orthopedic procedures, including arthroscopy, being approved and performed.

The region is also a hub for early adoption of next-generation technologies. UC Davis’s TMJ nano-arthroscopy program and Movora/VetClarity training initiatives demonstrate active development of new indications and expanded surgeon training, supporting both equipment sales and procedural growth.

 

Veterinary Arthroscopy Demand Drivers in Europe

Europe accounts for 30.0% of the market, valued at approximately USD 0.14 billion, and is projected to grow at a CAGR of 5.9%, benefiting from a large companion-animal population and a well-established referral network, with approximately 49% of European households owning at least one pet, representing a substantial base for veterinary care demand.

More importantly, Europe has a strong specialist infrastructure, with over 1,100 ECVS Diplomates supporting advanced surgical procedures across major markets such as the UK, Germany, France, and Scandinavia. Arthroscopy adoption is therefore concentrated in referral hospitals, universities, and high-volume specialty clinics.

Suppliers such as KARL STORZ benefit from integrated endoscopy ecosystems, allowing arthroscopy to be added to existing minimally invasive surgical platforms without requiring entirely separate imaging systems.

 

Why Asia-Pacific Is Becoming an Important Expansion Market

Asia-Pacific is an emerging but unevenly developed market for veterinary arthroscopy, accounting for a 20.0% market share valued at approximately USD 0.09 billion and is projected to grow at a CAGR of 7.8%. Growth is driven primarily by veterinary universities and referral hospitals investing in minimally invasive surgical capabilities. For example, GADVASU in India has procured 2.0-mm and 2.7-mm arthroscopes with accessories, reflecting institutional adoption of arthroscopy training and clinical services.

 

Market Outlook for Latin America, the Middle East and Africa

These regions represent smaller but growing markets, with arthroscopy adoption concentrated in urban referral hospitals, veterinary universities, and equine centers. Limited specialist availability, budget constraints, and infrastructure challenges restrict widespread adoption, but high-value cases in sport and performance animals continue to support demand. Latin America accounts for approximately 6.0% of the market, valued at around USD 0.03 billion, and is projected to grow at a CAGR of 6.3%, while the Middle East & Africa holds about 4.0% share, valued at nearly USD 0.02 billion, with an expected CAGR of 5.6%.

 

Who Will Lead the Competitive Race in the Veterinary Arthroscopy Devices Market Through 2032?

Arthrex Vet Systems Competitive Position in Veterinary Arthroscopy

Arthrex Vet Systems maintains a strong integrated position across veterinary orthopedics. Its portfolio includes conventional arthroscopes, imaging systems, resection tools, and the NanoScope platform. NanoScope combines a compact imaging sensor with LED illumination and digital control, supported by small-diameter instruments for diagnostic and operative use.

Its competitive advantage lies in integration across the full orthopedic workflow, combining imaging, instrumentation, and education while also expanding into disposable, procedure-linked revenue streams.

 

VetOvation and CONMED Market Contribution

VetOvation, in partnership with CONMED, offers a modular arthroscopy ecosystem that includes scopes, powered resection systems, irrigation equipment, and consumables. It also provides certified pre-owned systems, lowering entry barriers for smaller clinics.

This flexible model supports both capital equipment sales and recurring consumable revenue, making it attractive to practices with varying budget levels.

 

KARL STORZ Position in Veterinary Arthroscopy

KARL STORZ competes through its established reusable endoscopy ecosystem, offering arthroscopy telescopes, imaging systems, and documentation platforms. Its strength lies in cross-procedure integration, allowing clinics already using its systems for other minimally invasive procedures to extend into arthroscopy without major infrastructure changes.

 

B. Braun VetCare in the Competitive Landscape

B. Braun VetCare focuses on fluid management and procedural support, offering irrigation and suction systems used across arthroscopy and other minimally invasive procedures. While it does not compete directly in imaging systems, it captures recurring procedural demand through consumables and support equipment.

 

Biovision’s Strategy in Micro-Arthroscopy

Biovision Veterinary Endoscopy focuses on ultra-compact visualization through its 1.2-mm NeedleView system, designed for both diagnostic and operative arthroscopy in small animals and equine patients. Its approach reduces equipment size and procedural complexity, making arthroscopy more accessible in lower-resource or early-adoption settings.

 

Why Movora Uses Education as Part of Its Competitive Strategy

Movora, through VetClarity’s VetFocus Micro platform, combines micro-arthroscopy technology with structured training programs. These workshops focus on practical skills such as scope navigation, triangulation, and joint access techniques.

This strategy addresses a key barrier to adoption: surgeon confidence. By combining equipment with education, Movora aims to accelerate procedural adoption and improve utilization rates across new and existing users.

 

Analyst Perspective: What Will Determine Competitive Success Through 2032?

From an analyst standpoint, competitive success in the veterinary arthroscopy devices market through 2032 will be shaped less by standalone hardware innovation and more by ecosystem strength, procedural economics, and clinical adoption depth. Vendors that can bundle visualization, powered instrumentation, irrigation systems, and high-margin consumables into an integrated surgical workflow are likely to outperform those focused solely on premium scope technology.

A second key determinant will be procedure expansion enabled by miniaturization. Nano- and needle-arthroscopy platforms are expected to gradually shift arthroscopy from a referral-only orthopedic procedure toward broader diagnostic use in smaller joints and earlier-stage interventions. However, adoption will depend heavily on surgeon training, workflow simplicity, and demonstrable clinical outcomes rather than technology novelty alone.

 

Veterinary Arthroscopy Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.46 Billion
Revenue Forecast in 2032	USD 0.70 Billion
Overall Growth Rate	CAGR of 6.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By Animal Type, By End User, By Geography
By Product Type	Arthroscopes, Visualization Systems, Fluid Management Systems, Powered Resection Systems, Arthroscopic Hand Instruments, Accessories and Consumables
By Application	Diagnostic Arthroscopy, Surgical/Therapeutic Arthroscopy
By Animal Type	Companion Animals (Dogs, Cats), Large Animals (Horses, Other Large Animals)
By End User	Veterinary Hospitals, Veterinary Clinics, Veterinary Specialty and Referral Centers, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of minimally invasive veterinary orthopedic procedures, increasing companion animal healthcare spending, growing pet insurance coverage, expansion of veterinary specialty and referral centers, advancements in nano-arthroscopy and micro-visualization technologies, increasing demand for improved joint disease diagnosis and treatment
Customization Option	Available upon request